Novartis Pharma AG
100 articles with Novartis Pharma AG
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
BeiGene, Ltd. today announced an option, collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan.
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the closing of the collaboration and license agreement with Novartis Pharma AG, previously announced on January 11, 2021, to develop, manufacture, and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries BeiGene to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales BeiGene has the option to co-detail tislelizumab in North America Both parties have freedom to conduct combination trials globally CAMBRID
Tilak Healthcare Inks New Partnership Agreement in Ophthalmology With Novartis to Expand Internationally
Tilak Healthcare, a digital therapeutics pioneer specializing in the development of mobile medical application games used as monitoring and rehabilitation tools for chronic diseases, is proud to announce a framework agreement with Novartis Pharma AG for the promotion internationally of Tilak Healthcare’s first clinically validated mobile app for patient remo
Siemens Healthineers Announces Collaboration Agreement for Assay Development With an Initial Focus on Multiple Sclerosis
Siemens Healthineers and Novartis collaboration to develop assays supporting Novartis’ therapeutic pipeline. Initial program to focus on development of serum neurofilament light chain (NfL) immunoassay for patients with Multiple Sclerosis (MS) and other neurological diseases. Global distribution on Siemens Healthineers immunoassay platforms.
MorphoSys AG announced the end of the clinical development program of MOR106 in atopic dermatitis.
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals
Rapha Capital Management, LLC, an investment management firm located in Miami, Florida, and their associated entities announced their participation in a Series C financing for Poseida Therapeutics.
Elbit Imaging Ltd. Announces Its Indirect Associate, Gamida Cell, Has Entered Into Agreement With Novartis Pharma AG
Ophthotech Corporation Achieves Second $50 Million Enrollment Milestone Under Ex-US Licensing And Commercial Agreement With Novartis Pharma AG For Fovista
Proteus Digital Health, Inc. Grows Leadership Team And Board Of Directors With Former Executives From Novartis Pharma AG, Novartis Pharma AG And Egreetings Network
Unigene Laboratories, Inc. Announces Novartis Pharma AG' Disclosure of First Interpretable Results from Phase 3 Trial of Calcitonin (SMC021) in the Treatment of Post-menopausal Osteoporosis
Emisphere Technologies, Inc., Novartis Pharma AG. Nordic Bioscience A/S Provide Update on Osteoarthritis Phase III Study With Oral Calcitonin; Drug Deemed Safe But Not Effective, Emisphere Stock Falls 61.15% at 1:37PM EDT
Emisphere Technologies, Inc. Announces Expanded Collaboration Agreement With Novartis Pharma AG and Cancellation of Convertible Promissory Note
Emisphere Technologies, Inc. Partner Initiates Second Phase I Trial for Oral PTH Therapy for the Treatment of Postmenopausal Osteoporosis